An interventional study of Starting at high or low blood pressure in AKI, Continuous Renal Replacement Therapy and Dialysis, sponsored by Sahlgrenska University Hospital. Status unknown at 1 site in Sweden. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-04-18.
Sponsored by Sahlgrenska University Hospital · Not applicable, Interventional, and Prevention
Approximately 50% of patients in the intensive care unit (ICU) develop acute kidney injury (AKI) and more than 10% need dialysis. There is no treatment for AKI. Care is aiming for optimization of circulation and blood flow to the kidneys and avoiding nephrotoxic agents.
There is conflicting data concerning whether early or late dialysis is harmful for the kidneys. No one has examined the physiological changes in the kidney when starting dialysis and which blood pressure that leads to most optimal physiological conditions for the kidneys during dialysis. In this descriptive study of 20 ICU patients suffering from AKI we aim to investigate renal physiology when starting continuous renal replacement therapy (CRRT) and also at different target blood pressures using retrograde renal vein thermodilution technique. In parallel we will also investigate and validate this invasive method with contrast enhanced ultrasound of the kidneys.
2,030 studies on the registry are indexed under Renal Insufficiency; 168 are open to participants now.
This study's planned enrollment of 20 is below the median of 43 across 1,534 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Sahlgrenska University Hospital is the lead sponsor of 263 studies on the registry; 68 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AKI, according to KDIGO, stage 2 or 3 but with preserved urine production. Treated in the ICU at Sahlgrenska University Hospital Written, signed informed consent Male and female subjects ≥18 years
Exclusion Criteria:
Emergency need for dialysis Allergy to contrast media (used for CEUS)
Patients in this arm are randomized to have high target blood pressure at MAP 80-90 mmHg during the first recordings, thereafter they will receive low blood pressure target 60-70 mm Hg
Other: Starting at high or low blood pressure
Patients in this arm are randomized to have low target blood pressure at MAP 60-70 mmHg during the first recordings, thereafter they will receive high blood pressure target 80-90 mm Hg
Other: Starting at high or low blood pressure
Using norepinephrine, patients will receive high or low blood pressure to start with and after measurements cross to receive the other blood pressure target
Renal blood flow and CRRT
Changes in renal blood flow when CRRT is started? How will renal blood flow and oxygenation change at different blood pressure targets?
Time frame: 6 hours
Renal blood flow and blood pressure
Renal blood flow changes at different mean arterial blood pressure targets during CRRT?
Time frame: 6 hours
Glomerular filtration rate (GFR) and blood pressure
GFR changes at different mean arterial blood pressure targets during CRRT?
Time frame: 6 hours
Glomerular filtration rate (GFR) and CRRT
Changes in GFR when CRRT is started?
Time frame: 6 hours
Renal oxygenation during CRRT
Renal oxygenation before CRRT and during CRRT
Time frame: 6 hours
Renal oxygenation and blood pressure
Renal oxygenation changes at different mean arterial blood pressure targets during CRRT?
Time frame: 6 hours
Contrast enhanced renal ultrasound (CEUS)
Validation of CEUS compared to retrograde renal vein thermodilution in measuring renal blood flow
Time frame: 2 hours
atrial natriuretic peptide (ANP)
Differences in serum atrial natriuretic peptide (ANP) during CRRT
Time frame: 6 hours
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2020 (actual). Primary completion is estimated for Aug 2025, 57 months after the start.
Of 186 non-industry interventional studies with no phase under Renal Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 48. This study's planned 57 months is above that.
Counting every sponsor, half of 218 studies reached it within 22 months; a quarter within 8 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sahlgrenska University Hospital →